A dynamic combination of the best in science and health technology is filling unmet needs with more precise and effective treatments.
Science isn’t just in petri dishes anymore. Novel technology is increasingly involved. Discoveries are being made and tested in the cloud. Artificial intelligence and machine learning algorithms are digesting data lakes and helping drive new discoveries, speed development and provide smarter care.
Scientific innovation capabilities drive the biopharma sector both to develop treatments and manage global health. But science has changed—so how we innovate must also change. The way we measure benefits for patients and populations is going to shape the future.
In 2019, Accenture identified and defined New Science: a dynamic combination of the best in science and health technology that is driving more growth than originally predicted.
New Science is Accenture’s global analysis of regulated scientific treatments in both the pipeline and the market. It classifies science using different dimensions to understand its dynamics for patients, companies and markets. The dimensions include:
Enables better understand of future areas of growth in disease and overall therapeutic areas, and better manage portfolio risk.
Measuring treatments that qualify as achieving current unmet need ensures development of medicines for patient impact.
Measuring medicines that coexist with technology in the near-term and future ensures a better understanding of science’s growing dependence on tech.
Biopharma companies need a partner who understands how to combine technology and human ingenuity and work with you to “do the impossible”—provide better treatments in a more affordable, accessible way. We help do so across all areas of your business.
Embracing digital to speed up drug discovery and development, improve pipeline productivity and provide a better clinical trial experience.
Modernizing your commercial model to align evidence and economics to outcomes, design experiences for impact and engage with customers differently.
Creating a patient centric and intelligent supply chain that’s able to manufacture new and more complex products and innovative supplier partnerships.
Finding new ways to unlock data, increase collaboration, create more meaningful engagement and transform your culture to embrace new ways of working.
"The investment in scientific innovation is born by all stakeholders and felt most deeply by patients. Now the goal must be maximizing return on that investment for patients, too. There are better, faster ways to deliver innovation—2020 proved that."